ArticleJournal of gastrointestinal cancer2026
Pathological Complete Response in a Patient With HER2-Negative Esophagogastric Junction Cancer Undergoing Conversion-Intent Surgery After Ramucirumab Plus Paclitaxel Following Nivolumab-Based Chemotherapy: A Case Report.
Article in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNivolumab and other immune checkpoint inhibitors (ICIs) have improved survival in advanced gastric cancer. However, optimal management after progression on ICI-containing therapy remains uncertain. We report a case of HER2-negative esophagogastric junction (EGJ) cancer that showed a marked radiological and metabolic response to second-line ramucirumab plus paclitaxel (RAM + PTX) after nivolumab-based chemotherapy, allowing conversion-intent surgery, after which pathological complete response (pCR) was confirmed in the resected specimen. CASE PRESENTATION: A 76-year-old woman was diagnosed with advanced HER2-negative EGJ adenocarcinoma with para-aortic lymph node metastases (cT3N3bM1[Lym], Stage IVB according to the 15th edition of the Japanese Classification of Gastric Carcinoma). The tumor was classified as Siewert type III with minimal esophageal invasion. First-line SOX plus nivolumab was administered, but disease progression with mediastinal lymph node enlargement and suspected pulmonary metastases was observed after five cycles. Second-line RAM + PTX was subsequently initiated and resulted in marked regression of the primary tumor and metastatic lesions on computed tomography and endoscopy, with metabolic complete response on positron emission tomography-computed tomography. Although chemotherapy was temporarily interrupted because of immune-related type 1 diabetes mellitus, metabolic complete response was maintained after glycemic control with insulin therapy. Following multidisciplinary evaluation of treatment response and resectability, robot-assisted proximal gastrectomy with D2 lymphadenectomy and double-flap reconstruction was performed. Histopathological examination demonstrated no residual viable tumor cells (ypT0N0), consistent with pCR. The postoperative course was uneventful, and the patient remains clinically recurrence-free 10 months after surgery.
conclusionsThis case suggests that RAM + PTX after nivolumab-based chemotherapy may achieve substantial tumor regression in selected patients with advanced EGJ cancer and may provide an opportunity for conversion surgery. Robot-assisted proximal gastrectomy with double-flap reconstruction was feasible after successful systemic therapy. Careful multidisciplinary assessment and accumulation of further clinical evidence are needed to clarify the role of sequential systemic therapy and surgical intervention in this setting.
Indexed as
Identifiers
42541665What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.